Recently, a new open-label, randomized, controlled clinical trial, conducted by Garg et al. [19], showed that saxagliptin therapy was no less efficacious than the basal-bolus regimen in regard to glycaemic control in patients who had well-controlled T2D before hospitalization (HbA1c ≤7.5% on a ≤1 non-insulin lowering-glucose agent or HbA1c ≤7% on ≤2 non-insulin lowering-glucose agents). This evidence concerns the gene INS and type 2 diabetes mellitus.